MicroRNA profiling reveals age-dependent differential expression of nuclear factor κB and mitogen-activated protein kinase in adipose and bone marrow-derived human mesenchymal stem cells
© Pandey et al.; licensee BioMed Central Ltd. 2011
Received: 28 June 2011
Accepted: 14 November 2011
Published: 14 November 2011
Mesenchymal stem cells (MSCs) play a central role in mediating endogenous repair of cell and tissue damage. Biologic aging is a universal process that results in changes at the cellular and molecular levels. In the present study, the role of microRNA (miRNA) in age-induced molecular changes in MSCs derived from adipose tissue (ASCs) and bone marrow (BMSCs) from young and old human donors were investigated by using an unbiased genome-wide approach.
Human ASCs and BMSCs from young and old donors were cultured, and total RNA was isolated. The miRNA fraction was enriched and used to determine the expression profile of miRNA in young and old donor MSCs. Based on miRNA expression, differences in donor MSCs were further investigated by using differentiation assays, Western blot, immunocytochemistry, and bioinformatics.
Biologic aging demonstrated reduced osteogenic and adipogenic potential in ASCs isolated from older donors, whereas cell size, complexity, and cell-surface markers remained intact with aging. Analysis of miRNA profiles revealed that small subsets of active miRNAs changed secondary to aging. Evaluation of miRNA showed significantly decreased levels of gene expression of inhibitory kappa B kinase (IκB), interleukin-1α, inducible nitric oxide synthase (iNOS), mitogen-activated protein kinase/p38, ERK1/2, c-fos, and c-jun in MSCs from older donors by both bioinformatics and Western blot analysis. Nuclear factor kappa B (NF-κB), myc, and interleukin-4 receptor mRNA levels were significantly elevated in aged cells from both the adipose and bone marrow depots. Immunocytochemistry showed nuclear localization in young donors, but a cytosolic predominance of phosphorylated NF-κB in ASCs from older donors. Western blot demonstrated significantly elevated levels of NF-κB subunits, p65 and p50, and AKT.
These findings suggest that differential expression of miRNA is an integral component of biologic aging in MSCs.
Age-related changes occur in all biologic systems, from the phenotypic to the molecular level, leading to activation and deactivation of cellular pathways. Recent studies suggest that mesenchymal stem cells (MSCs) are subject to changes that accompany biologic aging [1–3]. MSCs, also known as mesenchymal stromal cells, are a multipotent, heterogeneous population of cells that possess the ability to differentiate along a variety of cell lineages. MSCs have been isolated from numerous tissue sources, including the bone marrow (BMSCs) and adipose tissue (ASCs), and have been shown to retain the ability to differentiate into numerous terminally differentiated cell types, including bone, cartilage, fat, muscle, and skin [4–6]. Studies also have investigated the role of MSCs as therapeutic agents in many disease states [4, 7]. It has been suggested that populations of MSCs are depleted with age and that reduction in MSC pools contributes to human aging and the onset of age-related disease processes [8, 9].
Biologic aging can affect not only the absolute numbers of MSCs, but also the expression profile of these cells [9–11]. Indeed, MSCs appear to be as susceptible as other cells to molecular alterations that result from in vivo biologic aging [2, 3, 12]. It has been suggested that MSCs isolated from older donors have an overall decline in differentiation potential or may show a greater propensity toward adipogenesis than toward other cell fates; however, most of these studies focused solely on BMSCs [1, 2, 13]. Other reports allude to a more complex pattern of events, especially with regard to the adipogenic potential of MSCs and aging . However, the changes exhibited by MSCs due to aging have not been fully delineated. Moreover, the effect of aging on the therapeutic potential of MSCs for regenerative medicine remains to be fully elucidated. It has been suggested that microRNAs (miRNAs) play an integral role in the regulation of aging and subsequent changes associated with the aging process [15–18]. Specifically, miRNAs, which are small 19- to 27-nucleotide (nt) RNA fragments, function in the translational regulation of gene expression. They are members of a large class of small noncoding RNAs. Degradation and repression of target mRNA transcripts are the primary mechanisms whereby miRNAs regulate gene expression and influence cellular processes and signaling mechanisms [19, 20]. It has been estimated that approximately two thirds of the whole mammalian genome may be influenced by translational regulation of gene expression by miRNA activity . Indeed, miRNAs appear to be integral regulators of gene expression, influencing processes that include aging, apoptosis, cancer, and inflammation [15, 22, 23].
Recent studies have investigated the role of miRNAs in MSCs as they progress from undifferentiated states to differentiated end-cell fates, in a variety of species [24, 25]. No investigations to date, however, have delved into the effects of biologic age-induced miRNA changes on MSCs. Given the potential of MSCs as cellular therapeutic agents, it is imperative to gain a full understanding of the effects of biologic aging on MSC properties, as well as the potential benefits and risks of using older or younger donor MSCs as treatment modalities.
In the current study, the alterations in the miRNA profiles of MSCs isolated from old and young donors were investigated, and significant downstream alterations that may be manifested secondary to biologic aging have been identified.
Materials and methods
Cell-culture materials, including Hank's buffered saline solution (HBSS), α-modified Eagle's medium (α-MEM), L-glutamine, penicillin/streptomycin, phosphate-buffered saline (PBS), and trypsin/EDTA were obtained from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from Atlanta Biological (Atlanta, GA). All reagents for miRNA and mRNA arrays were obtained from SABiosciences (Frederick, MD), including whole human genome miRNA array, signal-transduction pathway finder arrays, and RT2 First Strand Kits. Protease and phosphatase inhibitor cocktails, RIPA buffer, and BCA protein quantification kits were ordered from Thermo Scientific (Rockford, IL). Western blot reagents were obtained from Invitrogen; these included loading buffer, reducing agent, 4% to 12% Bis-Tris SDS-PAGE gels, iblot nitrocellulose membrane and blotting components, and chemiluminescence HRP developer kits. The chemiluminescence blocker was acquired from Millipore (Billerica, MA). All antibodies, both primary and secondary, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals used were molecular biology reagent grade.
Mesenchymal stem cell isolation and expansion
ASCs and BMSCs were isolated and expanded as previously reported . In brief, ASCs were isolated from subcutaneous white adipose tissue. BMSCs were obtained from the iliac crest or marrow discarded during orthopedic procedures [2, 26]. In brief, BMSCs were separated over a Ficoll gradient by centrifugation for 30 minutes at 1,800 g. Similarly, ASCs were isolated from subcutaneous white adipose tissue, after which the adipose tissue was digested with 0.075% collagenase for 30 minutes at 37°C to isolate ASCs. Subsequently, all cells were washed in HBSS or PBS, and then centrifuged at 300 g (ASC) or 1,000 g (BMSC) for 10 minutes. The pelleted nucleated cells were cultured overnight in a humidified atmosphere at 37°C with 5% CO2 in complete culture medium (CCM) for BMSCs, which consisted of α-MEM, 20% FBS, 1% L-glutamine, and 1% penicillin/streptomycin or stromal medium (SM) for ASCs (DMEM/F12, 10% FBS, 1% penicillin/streptomycin/amphotericin). The CCM was replaced every third day until the cells reached 70% to 80% confluence. All cells used were between passages 3 and 5 and identified as young donors (younger than 50 years) or old donors (older than 50 years). Young donors of ASCs were an average age of 31.5 ± 10.4 years, whereas BMSCs were 31.5 ± 8.7 years; old donors of ASCs were an average age of 63 ± 6.0 years, and old donors of BMSCs were an average age of 56.3 ± 5.0 years. Investigators were blinded to donor information about the ASCs and BMSCs; however, donor age, race, and other selected demographics were obtained. All donor groups had significant differences in age, but no other significant demographic differences, including BMI. All cells were isolated after review and approval by the institutional review board (IRB) of Tulane University School of Medicine, Pennington Biomedical Research Center, or Brigham and Women's Hospital, with informed patient consent.
Flow cytometry was performed as previously described . After MSCs were 70% confluent, CCM was aspirated, and cells were washed twice with PBS. Cells were harvested with trypsin, and resuspended in PBS for analysis. Cells were assessed for size by using forward and side light-scatter measurements. In addition, all cells were characterized by examination for cell-surface markers by using an extensive panel of antibodies developed by our Center over the past several-years period . Both BMSCs and ASCs expressed known MSC markers including CD29, CD44, CD90, CD105, CD166, and HLA class I. Both cell types were negative for lymphohematopoietic lineage markers, such as CD3, CD34, CD45, CD11b, and CD19.
The ability of MSCs to differentiate along osteogenic and adipogenic lineages was adapted from our previously described methods [29, 30]. In brief, cells were plated in 24-well plates and cultured in CCM until they attained 70% confluence. Culture medium was then aspirated and replaced with differentiation-specific medium. Osteogenic differentiation was assessed by staining for bone mineralization with Alizarin Red. Assessment of lipid inclusions, which indicate differentiation to adipocytes, was done by staining with Oil Red O solution, followed by microscopic examination on a Nikon Eclipse TE200 microscope (Nikon Instruments, Melville, NY). Differentiation was quantified as previously described . In brief, after cells were stained, they were destained by using 10% cetylpyridinium chloride for Alzarian Red and isopropyl alcohol for Oil Red O. Collected samples were then analyzed by using a microplate reader at 580 nm to assess the optical density (OD) of the collected samples. Sample OD values were then normalized to protein concentrations of the differentiated cells.
miRNA profiling arrays of MSCs
The microRNA profiling was performed by using the SABiosciences quantitative polymerase chain reaction (qPCR) array platform according to the protocols of the SABiosciences service core. In total, 16 donors, comprising four young and four old donors of ASCs and BMSCs, respectively, were analyzed with the whole human genome miRNA qPCR array. Samples of ASCs and BMSCs were pelleted and quantified to contain approximately 1 × 107 cells per donor. Cell pellets were flash frozen with liquid nitrogen and sent to the SABiosciences service core (Frederick, MD) for total RNA isolation, miRNA enrichment, qPCR-based array, and data report. The miRNA profile was analyzed for hierarchic clustering of miRNA by using Genesis to generate heatmaps (Genesis, Austria) . Genesis was also used to cluster donor profiles to identify individual donor variability.
Target generation from miRNA data
In addition to targets for miRNA action that have been validated in reported studies, potential targets for miRNA action were predicted by using putative targets generated from TargetScan Human V5.1. TargetScan Human predicts putative targets based on factors that include sequence homology, predicted biologic function, and verified targets. The predicted targets were ranked in order of conserved sequences and the prospect of regulation of gene expression via miRNA activity by using a context score, and previous studies have shown that context scores less than -0.3 are commonly considered biologically relevant . The predicted gene targets were analyzed with Ingenuity Pathways Assessment (IPA) and the Ingenuity Knowledgebase (Version 8.7, Ingenuity Systems, Redwood City, CA).
Bioinformatics analysis of generated miRNA targets
Targets generated by TargetScan were entered into IPA to delineate further the interactions and functions of miRNA on mRNA levels and the protein expression. IPA also generated lists of focus molecules, which were defined by direct and indirect molecules. Direct molecules were those input directly into IPA, such as the targets from TargetScan. Indirect molecules were those that have been described in previous studies, are commonly associated with the direct molecules, and are part of the Ingenuity Knowledgebase. IPA was used to gain insight into the interacting networks of the focus molecules, canonic pathway involvement, biologic functions, and cellular processes influenced by miRNA actions. Canonic pathways are those pathways in which miRNA may play integral roles in regulation. IPA analysis generates these canonic pathways based on the integration of inputted mRNA targets that were generated from significantly changed miRNA. Biologic functions are generated by IPA analysis investigating which physiological and pathological functions may be influenced by the inputted targets. Both the canonic pathways and biologic functions are then evaluated for statistical significance.
mRNA arrays of MSCs
Signal-transduction qPCR-based array was obtained from SABiosciences and was performed according to the manufacturer's instructions. In brief, total RNA isolated for the miRNA arrays was obtained from two ASC samples based on clustering of the miRNA profile of donors. Representative samples from young and old donors were selected for analysis. Total RNA samples (500 ng) were processed for cDNA synthesis by using a RT2 First Strand Kit according to the manufacturer's protocol. The Signal Transduction Pathway Finder array from SABiosciences was performed on a Bio-Rad CFX96 real-time PCR machine (Bio-Rad, Hercules, CA), according to the manufacturer's instructions. Data from the array were analyzed with the SABiosciences software by observed Ct values and determining the relative fold change as compared with housekeeping genes. Housekeeping genes used as internal controls included β2-microglobulin, hypoxanthine phosphoribosyltransferase 1, ribosomal protein L13a, glyceraldehyde-3-phosphate dehydrogenase, and β-actin.
Subcellular localization of NF-κB subunits by immunocytochemistry
Representative ASCs from old and young donors were selected based on hierarchic clustering of donors from miRNA analysis. Cells were plated at a density of 1 × 104 cells per 0.4 cm2. The next day, cells were fixed for 15 minutes at room temperature, washed, permeabilized for 5 minutes at room temperature, and washed again. Cells were incubated overnight at 4°C with a 1:200 dilution of p50 and p65 subunits of NF-κB, followed by 1 hour at room temperature with a 1:1,000 dilution of a goat anti-rabbit FITC secondary antibody. Slides were counterstained with DAPI, photographed with a Leica DMRXA2 microscope, and rendered with Slidebook software (Denver, CO).
Cell lysate and protein isolation
ASCs were grown in 15-cm2 dishes to 70% confluence at 37°C, as described earlier. Cells were washed twice with PBS and harvested with trypsin/EDTA. Cells were centrifuged, collected, flash frozen in liquid nitrogen, and stored at -80°C. Cell pellets were lysed in RIPA buffer (reference for RIPA buffer) containing protease and phosphatase inhibitor cocktails. Cell lysate was incubated on ice for 15 minutes with intermittent agitation, and clarified by centrifuging at 14,000 g for 15 minutes at 4°C. The supernatant was collected, and the protein concentration of samples was assessed by using a BCA kit and microplate reader (Optica). Protein samples were stored at -80°C until assayed.
Western blot analysis
Aliquots of 10 μg of total cellular protein from ASCs from old and young donor sample buffered with reducing agent were reduced, boiled, and placed on ice. Bis-Tris 4% to 12% SDS-PAGE gels were used to separate proteins of interest, which were transferred to a nitrocellulose membrane. The membranes were developed with chemiluminescence HRP developer according to the manufacturer's directions, and then immediately imaged by using the Image Quant LAS 4000 imager (GE Healthcare Life Sciences, Piscataway, NJ). Analysis and densitometry were performed with the Image Quant software and Image Quant imager.
The miRNA data were analyzed for relative fold changes from Ct values by using the 2-ΔΔCt method . Statistical significance was determined by comparisons of relative fold regulation of older versus younger donors, with a P value < 0.05 indicating significance. Data for miRNA were normalized to the average of four small RNA molecules, SNORD48, SNORD47, SNORD44, and RNU6. For analysis of mRNA data, relative fold changes were determined from Ct values by using the 2-ΔΔCt method. Statistical significance was determined by comparison of fold regulation of older with younger donors, with fold regulation more than equal or less than equal to ± 2, indicating significance. Additionally, P values were calculated for the miRNA expression profiles, and a P < 0.05 was used to identify those miRNAs whose fold changes were significant. IPA analysis used the right-tailed Fisher Exact test to calculate P values, with a P < 0.05 indicating significance of association to predicted targets and potential involvement in canonic pathways, biologic function, and networks assessment. All other data were analyzed with Sigma Plot by using a Student test, with P < 0.05 indicating statistical significance. All data are presented as mean ± standard error of the mean (SEM).
Characterization of MSCs
Changes in the miRNA profiles of ASCs and BMSCs secondary to biologic aging
MicroRNA target prediction and bioinformatics assessments
Age-related differences in constitutive mRNA expression in MSCs secondary to miRNA regulation
Age-dependent expression of MAPK/ERK and NF-κB in MSCs
In the present study, the comprehensive miRNA profiles of undifferentiated ASCs and BMSCs were analyzed to identify age-related differences in constitutive potential biologic functions at the mRNA and protein expression levels. The results showed that in MSCs isolated from two distinct tissues/organs, small subsets of miRNAs display age-related differences in the regulation of gene expression involving specific cellular and molecular pathways of cell proliferation and inflammation, presumably as regimented markers of aging. Specifically, significant age-related decreases were found in the MAPK/ERK pathway and NF-κB pathway expression.
Originally, it was thought that the hallmark of MSCs was their ability to differentiate into various end-cell types for regenerative repair of damage due to injury from disease processes [11, 35, 36]. Subsequently, many reports suggested that the role of MSCs as treatment modalities may occur through the expression of cytokines and chemokines that promote angiogenesis or squelch inflammatory responses, and adhesion molecules that would subsequently induce endogenous repair of injured cells and tissues . In addition to these mechanisms that MSCs use to ameliorate cellular damage, their differentiation capabilities remain an important defining characteristic. We confirmed that ASCs from young donors, compared with those from older donors, had significantly elevated potential to differentiate toward osteogenic and adipogenic lineages. Other studies found similar changes while investigating aging of MSCs from humans, mice, rhesus macaques, and cynomolgus monkeys [3, 30, 37, 38]. Our flow-cytometry results failed to detect changes in cell-surface markers secondary to the aging process. Thus, despite other age-related changes in MSCs, the cells can be identified by using cell-surface markers frequently used to distinguish MSCs from other cell types, regardless of the age of the donor .
Analysis revealed that individual targets selected from the IPA analysis followed the predicted pattern of expression at the mRNA and protein levels. All evaluated upregulated miRNA targets showed decreased levels of both mRNA and functional protein, including those involved in the MAPK/ERK and NF-κB pathways and in cell-cycle control. This is in accordance with recent results suggesting that although miRNAs promote both mRNA degradation and posttranslational repression, they appear to act predominantly as regulators at the mRNA level . Furthermore, the current findings suggest that the miRNA profile of MSCs can be used to identify potential signaling mechanisms involved in MSCs functions, and perhaps even provide another way to classify MSCs function.
Several recent reports have demonstrated the function of the let-7 family of miRNA and its role in MSCs, especially as markers and regulators of a differentiated state . The let-7 family was shown to repress cellular replication and inhibit self-renewal . Our data showed that let-7 family miRNA were significantly downregulated in both ASCs and BMSCs from older donors. Accordingly, it can be surmised that ASCs and BMSCs in older donors may not be as efficient at self-renewal and would have decreased overall proliferation, compared with younger donors. Other reports determined that human skeletal muscle cells from older donors demonstrate reduced expression of let-7 and decreased mRNA levels of cell-cycle regulators such as CDK6 . Our analysis of mRNA levels of cell-cycle regulatory molecules found that multiple cyclin-dependent kinases were downregulated, contributing to a reduction in cell proliferation. The data also showed increased miRNA targeted toward the Wnt/β-catenin-signaling pathway. Recent studies have shown that prolonged activation of Wnt signaling promotes MSC proliferation and contributes to aging . Thus, our results demonstrate that miRNA inhibits Wnt/β-catenin signaling to decrease cell proliferation in aged MSCs, and potentially plays a role in retarding the aging process in MSCs.
The miRNAs directed toward the MAPK/ERK system were expressed at higher levels in cells from older donors. Specifically, ERK1/2 and JNK gene expression were involved as putative targets for miRNA-mediated gene-expression control. The downregulation of mRNA levels for c-fos and c-jun were confirmed by using real-time PCR and, by Western blot, demonstrated decreased protein levels of the MAPK pathway. Collectively p38, p-ERK1/2, p-c-fos, p-c-jun, and p-JNK levels were all significantly reduced in the ASCs of older donors as compared with those of younger donors, with the extension to BMSCs due to a similar miRNA profile and IPA analysis. Previous studies have indicated that BMSCs from older donors have decreased proliferation potential [2, 42, 43]. Additional reports have suggested that the dynamics of the aging process of MSCs is a determinant of cellular aging; however, the exact mechanism remains unclear . The identified differences in miRNA in cells from older donors may represent the mechanism by which MSCs, through control over the MAPK/ERK signaling cascade, decrease cellular proliferation rates, thereby contributing to reduced tissue renewal in aging.
Although many of the fine details of aging in humans are yet to be elucidated, the interplay of aging and inflammation has been intensively researched. Many abnormalities in cellular processes have been found to occur with aging, including the development of cancer and type II diabetes mellitus [17, 44]. At the center of these disease processes lie the common denominators of advanced age and inflammation. Interestingly, elevated levels of activated NF-κB were observed in older-donor MSCs. Whereas regulatory and traditional components of the NF-κB pathway, including, among others, IκB, IκK, iNOS, and IL-1α, were downregulated, other nontraditionally associated molecules were upregulated, including IL-4 receptor and myc oncogene. Traditionally, protein factors responsive to NF-κB transcriptional regulation would further amplify NF-κB expression, which was not observed in the current study . In addition, the subcellular distribution of NF-κB observed in MSCs from older donors suggests the possibility of an alternative role in MSCs aging. Aging and NF-κB activation may have more in common than was initially postulated. Previous reports indicated that NF-κB can function in resistance to apoptosis . In addition, NF-κB was shown to repress apoptosis triggered by JNK . These observations, combined with our data showing decreased levels of JNK, provide evidence that NF-κB may be central to a protective role in MSC aging. Indeed, our data demonstrate that elevated levels of NF-κB regulated by miRNA activity may play a central role in the onset and progression of the aging process in MSCs.
The results also suggest that a delicate balance is maintained as a result of increased NF-κB expression in older MSCs. Typically, elevated levels of NF-κB are linked with pathologic processes; in old cells, however, elevated levels of NF-κB could prevent apoptosis . Prevention of apoptosis would be of substantial importance to MSCs, especially given their function for endogenous cellular repair. Most studies, however, have demonstrated a potent anti-inflammatory role for MSCs . The paradigm shift occurs with the notion of how a potently anti-inflammatory cell would maintain elevated levels of NF-κB. Our results demonstrated that although NF-κB levels are indeed elevated in older donors, presumably to prevent activation of apoptotic pathways, other commonly associated molecules in the NF-κB and inflammatory cascade were downregulated. IPA analysis, mRNA expression, and protein levels demonstrated that molecules such as IL-1α, TNF-α, iNOS, and IκK were significantly downregulated in ASCs from older donors. In addition, JNK was also significantly downregulated in older donors, giving support to the role of NF-κB as an inhibitor of apoptosis. That IκB levels decreased in the older donor ASCs is indicative of prolonged NF-κB activity. Although the classic NF-κB activity simultaneously causes de novo synthesis of IκB, it appears that NF-κB levels that are elevated because of aging in MSCs do not work through this mechanism. Intracellular localization of NF-κB from the current study in cells from younger donors appeared more predominant in the nucleus, specifically in the nucleolus, whereas cells from older donors demonstrated accumulation of NF-κB in the cytosol; these observations suggest that although it was phosphorylated in both groups, NF-κB was functioning differently as a function of age. Alternatively, relocalization of NF-κB subunits to the cytosol may indicate a lack of transcriptional activity, as further evidenced by decreased pro-inflammatory cytokines and other molecules including IL-1α, IL-8, and iNOS mRNA levels in cells from older donors compared with younger donors. Further investigation of the role of elevated NF-κB levels is required to gain a full understanding of the mechanisms at work in the MSC aging process.
In summary, miRNA profiling demonstrated that subsets of miRNAs are biologically active in human MSCs, with the profiles of miRNAs changing with aging in both ASCs and BMSCs. Furthermore, miRNAs modulate and regulate gene expression related to a variety of functions, particularly cellular proliferation and inflammation, both of which play an integral role in the process of aging. ASCs from older donors also exhibit significantly elevated levels of NF-κB, perhaps in response to downregulation of the MAPK/ERK system to prevent proliferation and inhibit apoptotic stimuli. Interestingly, other molecules commonly associated with NF-κB were downregulated, leading to a unique and novel constellation of expression of the core inflammatory molecules in a potently anti-inflammatory cell. The current study presents, to our knowledge, the first report that miRNAs have unique roles in the aging of MSCs, maintaining their capacity to suppress inflammation and promote endogenous cellular repair while, perhaps, allowing MSCs to escape the aging process.
adipose-derived mesenchymal stem cells
bone marrow-derived mesenchymal stem cells
complete culture medium
Ingenuity Pathway Assessment
mitogen activated protein kinase
messenger ribonucleic acid
micro ribonucleic acid
mesenchymal stem cells
nuclear factor kappa B
polymerase chain reaction.
We thank Alan Tucker for his excellent technical assistance in performing flow cytometry. We also thank Margie McCants and Christina McLennan for their technical assistance with cell culture and Dina Gaupp for her tremendous help with immunocytochemistry. We thank Drs. James Wade, Ann Reilley, and Michael Teague, together with their office staff and patients, for donating adipose tissues to this project. JMG is the Founder of LaCell, LLC, and serves as a consultant for Johnson & Johnson companies ATRM and Mentor. The research was supported by grant numbers RR00164 from the National Center for Research Resources, R21-NS059665 National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Pennington Biomedical Research Center, and Tulane University.
- Tokalov SV, Gruner S, Schindler S, Wolf G, Baumann M, Abolmaali N: Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. Stem Cells Dev. 2007, 16: 439-446. 10.1089/scd.2006.0078.View ArticlePubMedGoogle Scholar
- Zhou S, Greenberger JS, Epperly MW, Goff JP, Adler C, Leboff MS, Glowacki J: Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008, 7: 335-343. 10.1111/j.1474-9726.2008.00377.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Yu JM, Wu X, Gimble JM, Guan X, Freitas MA, Bunnell BA: Age-related changes in mesenchymal stem cells derived from rhesus macaque bone marrow. Aging Cell. 2011, 10: 66-79. 10.1111/j.1474-9726.2010.00646.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Gimble JM, Guilak F, Bunnell BA: Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther. 2010, 1: 19-10.1186/scrt19.PubMed CentralView ArticlePubMedGoogle Scholar
- Izadpanah R, Joswig T, Tsien F, Dufour J, Kirijan JC, Bunnell BA: Characterization of multipotent mesenchymal stem cells from the bone marrow of rhesus macaques. Stem Cells Dev. 2005, 14: 440-451. 10.1089/scd.2005.14.440.View ArticlePubMedGoogle Scholar
- Prockop DJ: Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther. 2009, 17: 939-946. 10.1038/mt.2009.62.PubMed CentralView ArticlePubMedGoogle Scholar
- Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG: Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA. 2007, 104: 11002-11007. 10.1073/pnas.0704421104.PubMed CentralView ArticlePubMedGoogle Scholar
- Stolzing A, Jones E, McGonagle D, Scutt A: Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008, 129: 163-173. 10.1016/j.mad.2007.12.002.View ArticlePubMedGoogle Scholar
- Van Zant G, Liang Y: The role of stem cells in aging. Exp Hematol. 2003, 31: 659-672. 10.1016/S0301-472X(03)00088-2.View ArticlePubMedGoogle Scholar
- Carrington JL: Aging bone and cartilage: cross-cutting issues. Biochem Biophys Res Commun. 2005, 328: 700-708. 10.1016/j.bbrc.2004.12.041.View ArticlePubMedGoogle Scholar
- Rao MS, Mattson MP: Stem cells and aging: expanding the possibilities. Mech Ageing Dev. 2001, 122: 713-734. 10.1016/S0047-6374(01)00224-X.View ArticlePubMedGoogle Scholar
- Mareschi K, Ferrero I, Rustichelli D, Aschero S, Gammaitoni L, Aglietta M, Madon E, Fagioli F: Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem. 2006, 97: 744-754. 10.1002/jcb.20681.View ArticlePubMedGoogle Scholar
- Zheng H, Martin JA, Duwayri Y, Falcon G, Buckwalter JA: Impact of aging on rat bone marrow-derived stem cell chondrogenesis. J Gerontol A Biol Sci Med Sci. 2007, 62: 136-148. 10.1093/gerona/62.2.136.View ArticlePubMedGoogle Scholar
- Karagiannides I, Tchkonia T, Dobson DE, Steppan CM, Cummins P, Chan G, Salvatori K, Hadzopoulou-Cladaras M, Kirkland JL: Altered expression of C/EBP family members results in decreased adipogenesis with aging. Am J Physiol Regul Integr Comp Physiol. 2001, 280: R1772-1780.PubMedGoogle Scholar
- Hackl M, Brunner S, Fortschegger K, Schreiner C, Micutkova L, Muck C, Laschober GT, Lepperdinger G, Sampson N, Berger P: miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging. Aging Cell. 2010, 9: 291-296. 10.1111/j.1474-9726.2010.00549.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Liang R, Bates DJ, Wang E: Epigenetic control of microRNA expression and aging. Curr Genomics. 2009, 10: 184-193. 10.2174/138920209788185225.PubMed CentralView ArticlePubMedGoogle Scholar
- Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, Evans MK: microRNA expression patterns reveal differential expression of target genes with age. PLoS One. 2010, 5: e10724-10.1371/journal.pone.0010724.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang E: MicroRNA, the putative molecular control for mid-life decline. Ageing Res Rev. 2007, 6: 1-11. 10.1016/j.arr.2007.02.004.View ArticlePubMedGoogle Scholar
- Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010, 466: 835-840. 10.1038/nature09267.PubMed CentralView ArticlePubMedGoogle Scholar
- Pillai RS, Bhattacharyya SN, Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms?. Trends Cell Biol. 2007, 17: 118-126. 10.1016/j.tcb.2006.12.007.View ArticlePubMedGoogle Scholar
- Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19: 92-105.PubMed CentralView ArticlePubMedGoogle Scholar
- Subramanian S, Steer CJ: MicroRNAs as gatekeepers of apoptosis. J Cell Physiol. 2010, 223: 289-298.PubMedGoogle Scholar
- Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP: The impact of microRNAs on protein output. Nature. 2008, 455: 64-71. 10.1038/nature07242.PubMed CentralView ArticlePubMedGoogle Scholar
- Bae S, Ahn JH, Park CW, Son HK, Kim KS, Lim NK, Jeon CJ, Kim H: Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fibroblasts. Cell Tissue Res. 2009, 335: 565-573. 10.1007/s00441-008-0729-y.View ArticlePubMedGoogle Scholar
- Drummond MJ, McCarthy JJ, Sinha M, Spratt HM, Volpi E, Esser KA, Rasmussen BB: Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis. Physiol Genomics. 2010, 43: 595-603.PubMed CentralView ArticlePubMedGoogle Scholar
- Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, Bunnell BA: Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem. 2006, 99: 1285-1297. 10.1002/jcb.20904.PubMed CentralView ArticlePubMedGoogle Scholar
- Tucker HA, Bunnell BA: Characterization of human adipose-derived stem cells using flow cytometry. Methods Mol Biol. 2010, 702: 121-131.View ArticleGoogle Scholar
- Pachon-Pena G, Yu G, Tucker A, Wu X, Vendrell J, Bunnell BA, Gimble JM: Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol. 2011, 226: 843-851. 10.1002/jcp.22408.PubMed CentralView ArticlePubMedGoogle Scholar
- Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C: Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008, 45: 115-120. 10.1016/j.ymeth.2008.03.006.PubMed CentralView ArticlePubMedGoogle Scholar
- Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA: Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 2008, 68: 4229-4238. 10.1158/0008-5472.CAN-07-5272.PubMed CentralView ArticlePubMedGoogle Scholar
- Ripoll CB, Bunnell BA: Comparative characterization of mesenchymal stem cells from eGFP transgenic and non-transgenic mice. BMC Cell Biol. 2009, 10: 3-10.1186/1471-2121-10-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Sturn A, Quackenbush J, Trajanoski Z: Genesis: cluster analysis of microarray data. Bioinformatics. 2002, 18: 207-208. 10.1093/bioinformatics/18.1.207.View ArticlePubMedGoogle Scholar
- Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007, 27: 91-105. 10.1016/j.molcel.2007.06.017.PubMed CentralView ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, Neutzel S, Sharkis SJ: Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001, 105: 369-377. 10.1016/S0092-8674(01)00328-2.View ArticlePubMedGoogle Scholar
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.View ArticlePubMedGoogle Scholar
- Katsara O, Mahaira LG, Iliopoulou EG, Moustaki A, Antsaklis A, Loutradis D, Stefanidis K, Baxevanis CN, Papamichail M, Perez SA: Effects of donor age, gender and in vitro cellular aging on the phenotype, functional and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2011, 20: 1549-1561. 10.1089/scd.2010.0280.View ArticlePubMedGoogle Scholar
- Ren Z, Wang J, Zou C, Guan Y, Zhang YA: Comparative characterization of mesenchymal stem cells from different age groups of cynomolgus monkeys. Sci China Life Sci. 2010, 53: 563-572. 10.1007/s11427-010-0083-7.View ArticlePubMedGoogle Scholar
- Hammond SM, Sharpless NE: HMGA2, microRNAs, and stem cell aging. Cell. 2008, 135: 1013-1016. 10.1016/j.cell.2008.11.026.PubMed CentralView ArticlePubMedGoogle Scholar
- Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007, 67: 7713-7722. 10.1158/0008-5472.CAN-07-1083.View ArticlePubMedGoogle Scholar
- Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS: mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell. 2009, 5: 279-289. 10.1016/j.stem.2009.06.017.PubMed CentralView ArticlePubMedGoogle Scholar
- Kassem M: Stem cells: potential therapy for age-related diseases. Ann N Y Acad Sci. 2006, 1067: 436-442. 10.1196/annals.1354.062.View ArticlePubMedGoogle Scholar
- Stenderup K, Justesen J, Clausen C, Kassem M: Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003, 33: 919-926. 10.1016/j.bone.2003.07.005.View ArticlePubMedGoogle Scholar
- Salminen A, Kaarniranta K: NF-kappaB signaling in the aging process. J Clin Immunol. 2009, 29: 397-405. 10.1007/s10875-009-9296-6.View ArticlePubMedGoogle Scholar
- Salminen A, Ojala J, Kaarniranta K: Apoptosis and aging: increased resistance to apoptosis enhances the aging process. Cell Mol Life Sci. 2010, 68: 1021-1031.View ArticlePubMedGoogle Scholar
- Karin M: NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspect Biol. 2009, 1: a000141-10.1101/cshperspect.a000141.View ArticleGoogle Scholar
- Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, Dean K, Franzoso G: The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 2006, 13: 712-729. 10.1038/sj.cdd.4401865.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.